Financials
Financial year 2025
PATHOMATION from Antwerpen, company number BE0500694204, closed financial year 2025 with a result of € -402,294 after tax. For that financial year PATHOMATION recorded a gross margin of € 568,228 and equity of € 890,585. Compared with financial year 2024, the result moved from € 7,002 to € -402,294. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 16, 2026.
€ 890,585
▼ 31% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -402,294
▼ still € 7,002 profit in 2024
Profit after tax over the fiscal year.
€ 109,401
▼ 88% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 665.
People and assets in 2025
7.4
▲ 2.2 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 617,444
▲ 51% vs 2024
€ 83,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 17,082
▲ € 16,069 vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 116,181
▼ 45% vs 2024
€ 20,767 is repaid this year. At this pace the long-term loan is gone in ≈ 5 years.
€ 78,646
▼ 85% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 66,481
▲ 21% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 445,114 | € 739,917 | € 684,218 | € 568,228 | ▼ 17% |
| Profit after taxes | € -125,164 | € 105,141 | € 7,002 | € -402,294 | ▼ € 409,296 |
| Equity | € 380,816 | € 485,957 | € 1,292,879 | € 890,585 | ▼ 31% |
| Total debts | € 537,401 | € 566,082 | € 1,355,539 | € 808,477 | ▼ 40% |
| Cash | € 30,552 | € 40,518 | € 912,228 | € 109,401 | ▼ 88% |
| Land & buildings | € 3,397 | - | - | - | |
| Retained profit | € 290,816 | € 395,957 | € 402,959 | € 665 | ▼ € 402,294 |
| Bank debt | € 158,773 | € 124,727 | € 211,383 | € 116,181 | ▼ 45% |
| Balance sheet total | € 918,216 | € 1,052,039 | € 2,648,418 | € 1,699,061 | ▼ 36% |
| Employees (FTE) | 4.8 | 4.9 | 5.2 | 7.4 | ▲ 2.2 |
By gross margin, PATHOMATION ranks 16th of 59 companies with main activity “Ontwerpen van computerprogramma’s” in Antwerpen that publish figures (fiscal year 2025).
Key figures of PATHOMATION, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
Ask about PATHOMATION the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to PATHOMATION?
What happened at PATHOMATION in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 402,294 (▼ € 409,296 vs 2024). Source: NBB ↗
- Heitbrink Teixidor SL became a director. NBB
- CellCarta NV became a director. NBB
- Kockx-Consulting BV stepped down as director. NBB
- Capital increase of € 799,920, published in the Gazette. Source: Staatsblad ↗
- Incorporation, published in the Gazette. Source: Staatsblad ↗
- New establishment in Antwerpen. KBO
In short
From € 125,164 loss in 2022 to € 402,294 loss in 2025.
Paid € 10,766 in corporate taxes since 2022.
Best year ever: 2023, with € 105,141 profit.
On average € 76,800 of value added per employee in 2025.
Management
The stake of CellCarta comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
PATHOMATIONBehind PATHOMATION are Histodig BV, Heitbrink Teixidor SL and CellCarta NV. The shares are held by CellCarta (18.5%).
Directors
According to the 2025 annual accounts
Director · represented by Filip Heitbrink
since 2026
since 2026
Director · represented by Mark Kockx
Also active at: BATYO, CellCarta, HistoGeneX Holding, Arsenal IO Belgium
· until 2026
Shareholders
CellCarta · holding of CellCarta NV
18.5%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Prinses Joséphine Charlottelaan 10
2600 Antwerpen
Sint-Bavostraat 78-80
2610 Antwerpen
Active since 8 November 2012
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Similar companies in Antwerpen
Same main activity (Ontwerpen van computerprogramma’s), 88 active companies in Antwerpen, largest first.
€ 24.6 million revenue · 2025
€ 17.4 million revenue · 2025
€ 10.3 million gross margin · 2025
€ 7.6 million revenue · 2025
€ 6.1 million gross margin · 2025
€ 3.9 million gross margin · 2025
Shareholders according to the Official Gazette deeds
Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.
Incorporation
Source: Deed ↗- WAELPUT Wim Joris(vennoot) 33.3%
- HISTOGENEX(vennoot) 33.3%
- SUCAET Yves Marie-Claire Antoine(vennoot) 33.3%
Details
- Company number
- 0500.694.204
- VAT number
- BE 0500.694.204
- Registered office
- Prinses Joséphine Charlottelaan 10, 2600 Antwerpen
- Names & denominations
- PATHOMATION
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 8 November 2012
- Peppol
- Active · Active since 4 Apr 2025
- Activities · NACE
Ontwerpen van computerprogramma’s
Ontwerpen en programmeren van computerprogramma's
Activiteiten op het gebied van computerconsultancy en beheer van computerfaciliteiten
Computerconsultancy-activiteiten